Myeloma Minute: Forecast for 2019 in myeloma: changes, challenges
|
| INNOVATION | Latest Research
Prescription for Weathering the Changes and Challenges of 2019? A Strong Dose of ResilienceThe new year is delivering plenty of news that will impact the myeloma community. “The very good news is that the commitment to myeloma research and new drug development is at an all-time high,” says IMF Chairman Brian G.M. Durie, MD. But high prices and environmental threats persist, making it a good time to “calmly recalibrate your personal navigation systems and chart a new way forward.”
|
|
|
| INNOVATION | Latest Research
|
| INSPIRATION | Fundraiser
|
Best of ASH 2018 Teleconference |
Register Now for the 3rd Annual Masters Tennis for Myeloma Fundraiser |
|
During the Best of ASH 2018 teleconference on Thursday, January 10, 2019, at 4 p.m. PST / 7:00 p.m. EST, IMF Chairman of the Board Dr. Brian G.M. Durie will highlight key takeaways for multiple myeloma patients and caregivers from the thousands of medical abstracts presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. You don’t want to meet this exciting 60-minute discussion, which includes a Q & A with callers. |
The 3rd Annual Masters Tennis for Myeloma Fundraiser takes place from 2 p.m. - 4 p.m. on Saturday, March 9, 2019, at the Glenview Champions Tennis Club (3140 Glenview Road) in The Villages, Florida. Hosted by Ed Curtis, the event honors the memory of Carolyn Curtis. All proceeds from this event will benefit The Villages Multiple Myeloma Support Group, which Carolyn Curtis founded. To register or play for the event, contact Ed Curtis at 352-399-5022 or at [email protected]. |
|
|
|
|
| ACTION | Government Shutdown
Government Shutdown Affects FDA OperationsOn December 22, 2018, the Food and Drug Administration (FDA) entered a “lapse period” where funding for the agency through congressional appropriations ran out. The ongoing lapse period will continue until an agreement is made on a fiscal year 2019 appropriations bill, or a continuing resolution is passed to provide operational funds. During this funding lapse, the FDA will have limited functionality and may engage in only the following activities: (1) activities necessary to address imminent threats to the safety of human life and (2) activities funded by carryover funds, including but not limited to user fees. Examples of operational core functions can be found on this statement from the FDA, and include supporting medical product recalls when products endanger patients, as well as screening medical products imported into the U.S. Much of the remainder of the Department of Health and Human Services (HHS), of which the FDA is a part, will remain open. Here is a statement from HHS on what services will be affected by the shutdown. The IMF Advocacy Team will continue to monitor how the government shutdown could impact patient health and provide information when needed. Learn more by contacting IMF Advocacy at the link below.
|
|
|
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series
|
|
CLINICAL TRIALS |
EVENTS |
|
New isatuximab Clinical Trial: the IMROZ Study New isatuximab Clinical Trial: the IKEMA Study Join the conversation about myeloma on the Smart Patients Message Board |
March 15-16, 2019 March 23, 2019 April 5-6, 2019 April 6, 2019 May 11, 2019 |
Amgen, Celgene Corporation, Genentech, Sanofi-Genzyme, and Takeda Oncology
and individuals like you who supported the IMF this year